With 5.61 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.22 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.165 whereas the lowest price it dropped to was $1.81. The 52-week range on RVPH shows that it touched its highest point at $5.21 and its lowest point at $0.60 during that stretch. It currently has a 1-year price target of $15.00. Beta for the stock currently stands at -0.12.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RVPH was up-trending over the past week, with a rise of 10.50%, but this was up by 39.86% over a month. Three-month performance surged to 65.29% while six-month performance rose 66.67%. The stock lost -61.46% in the past year, while it has gained 10.50% so far this year. A look at the trailing 12-month EPS for RVPH yields -1.11 with Next year EPS estimates of -0.84. For the next quarter, that number is -0.22. This implies an EPS growth rate of 40.00% for this year and 14.95% for next year.
Float and Shares Shorts:
At present, 46.58 million RVPH shares are outstanding with a float of 39.69 million shares on hand for trading. On 2024-10-31, short shares totaled 5.3 million, which was 1584.0000000000002 higher than short shares on 1727654400. In addition to Dr. Laxminarayan Bhat Ph.D. as the firm’s Founder, CEO, President & Director, Mr. Narayan Prabhu serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.30066 of RVPH’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, RVPH reported revenue of $0.0 and operating income of -$8462534.0. The EBITDA in the recently reported quarter was -$8432973.0 and diluted EPS was -$0.25.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RVPH since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RVPH analysts setting a high price target of 17.0 and a low target of 12.0, the average target price over the next 12 months is 14.8. Based on these targets, RVPH could surge 750.0% to reach the target high and rise by 500.0% to reach the target low. Reaching the average price target will result in a growth of 640.0% from current levels.
Analysts have provided yearly estimates in a range of -$0.9603 being high and -$1.0296 being low. For RVPH, this leads to a yearly average estimate of -$0.99.
